论文部分内容阅读
目的 探讨CYFRA 2 1 1在血清中的表达及其对非小细胞肺癌的诊断、病情监测及疗效判定的临床应用价值。方法分别在手术、放疗或化疗前后 2周内采集非小细胞肺癌患者血清标本共 16 9份。采用放射免疫分析方法检测样本血清中CYFRA2 1 1的表达情况。结果 非小细胞肺癌患者血清CYFRA 2 1 1总体表达水平为 (12 .98± 7.34) μg/L ,其中鳞癌为 (2 0 .48± 11.2 5 )μg/L ,腺癌为 (5 .48± 3 .43) μg/L ,且随病情的发展而升高。检测总体阳性率为 5 6 .80 % ,其中鳞癌为 70 .96 % ,腺癌为 2 6 .32 %。鳞癌患者血清表达水平及检测阳性率均显著高于腺癌患者 (P <0 .0 5 ) ,血清CYFRA 2 1 1的表达水平在术后 2周显著下降 (P <0 .0 5 )。病情稳定、疗效较好的患者血清CYFRA 2 1 1表达无明显变化 ,病情进展、疗效较差的患者则明显升高 (P <0 .0 5 )。结论 CYFRA 2 1 1表达水平对非小细胞肺癌的诊断、病情监测及疗效判定均有较好的临床应用价值
Objective To investigate the expression of CYFRA 2 1 1 in serum and its clinical value in diagnosis, diagnosis and treatment of non-small cell lung cancer. Methods A total of 16 9 serum samples from patients with non-small cell lung cancer were collected before and after surgery, radiotherapy or chemotherapy. Radioimmunoassay was used to detect the expression of CYFRA2 1 1 in the sample serum. Results The overall serum level of CYFRA 2 1 1 in non-small cell lung cancer patients was (12.98 ± 7.34) μg / L, with squamous cell carcinoma (20.48 ± 11.2 5) μg / L and adenocarcinoma (5.48 ± 3.43) μg / L, and increased with the progression of the disease. The overall detection rate was 56.8%, of which squamous cell carcinoma was 70.96% and adenocarcinoma was 26.32%. Serum levels of the patients with squamous cell carcinoma and their positive rates were significantly higher than those of patients with adenocarcinoma (P <0.05). The serum levels of CYFRA 2 1 1 were significantly decreased 2 weeks after surgery (P <0.05). The patients with stable disease and good curative effect showed no significant change in the expression of serum CYFRA 2 1 1, but the progression of disease and the patients with poor curative effect were significantly higher (P <0.05). Conclusion The expression level of CYFRA 2 1 1 has a good clinical value in diagnosis, condition monitoring and curative effect evaluation of non-small cell lung cancer